Stoke Therapeutics (NASDAQ:STOK) Insider Sells $170,065.15 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 5,545 shares of the company’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $30.67, for a total transaction of $170,065.15. Following the completion of the sale, the insider directly owned 20,110 shares in the company, valued at approximately $616,773.70. The trade was a 21.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Barry Ticho also recently made the following trade(s):

• On Tuesday, August 18th, Barry Ticho sold 4,767 shares of Stoke Therapeutics stock. The shares were sold at an average price of $32.03, for a total transaction of $152,687.01.
• On Monday, August 3rd, Barry Ticho sold 7,176 shares of Stoke Therapeutics stock. The stock was sold at an average price of $29.04, for a total value of $208,391.04.

Stoke Therapeutics Price Performance

NASDAQ STOK traded down $0.51 during trading on Thursday, reaching $29.99. 510,577 shares of the company’s stock were exchanged, compared to its average volume of 763,995. The business has a 50 day moving average price of $31.23 and a 200-day moving average price of $32.23. The stock has a market capitalization of $1.94 billion, a P/E ratio of -8.98 and a beta of 1.23. Stoke Therapeutics, Inc. has a fifty-two week low of $18.80 and a fifty-two week high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The business had revenue of $9.32 million during the quarter, compared to the consensus estimate of $4.89 million. On average, analysts forecast that Stoke Therapeutics, Inc. will post -3.52 earnings per share for the current year.

Institutional Trading of Stoke Therapeutics

Several institutional investors have recently added to or reduced their stakes in STOK. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Stoke Therapeutics by 5.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock valued at $162,000 after buying an additional 1,149 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Stoke Therapeutics by 21.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock worth $11,053,000 after buying an additional 293,072 shares in the last quarter. Jane Street Group LLC boosted its position in shares of Stoke Therapeutics by 125.2% in the first quarter. Jane Street Group LLC now owns 26,978 shares of the company’s stock valued at $179,000 after acquiring an additional 15,001 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Stoke Therapeutics by 26.6% in the second quarter. JPMorgan Chase & Co. now owns 25,655 shares of the company’s stock valued at $291,000 after acquiring an additional 5,398 shares during the period. Finally, Rhumbline Advisers grew its stake in shares of Stoke Therapeutics by 33.9% in the second quarter. Rhumbline Advisers now owns 66,419 shares of the company’s stock valued at $754,000 after acquiring an additional 16,820 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on STOK. Wedbush raised their price target on Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Guggenheim reiterated a “buy” rating and issued a $60.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, August 4th. The Goldman Sachs Group initiated coverage on shares of Stoke Therapeutics in a research report on Monday, July 13th. They issued a “buy” rating and a $44.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on shares of Stoke Therapeutics in a research note on Friday, August 21st. They set an “overweight” rating and a $40.00 target price for the company. Finally, Canaccord Genuity Group reduced their target price on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Stoke Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $44.25.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.